Stock Price & Analysis

Based on the recent data and news, here's a concise analysis of GEHC stock:

Technical Analysis

The stock shows strong bullish momentum, with price currently at $91.46 in pre-market trading. The stock has broken above key resistance levels and is trading well above its major moving averages, indicating positive technical strength.

Recent Catalysts

• Strong Q4 2024 earnings beat with EPS of $1.45 vs $1.26 consensus
• Revenue of $5.32 billion, roughly in-line with expectations
• Robust margin expansion with adjusted EBIT margin improving to 18.7%
• Positive 2025 guidance with organic revenue growth of 2-3% and adjusted EPS of $4.61-$4.75

Current Market Position

• Trading near 52-week highs with strong momentum
• Fibonacci resistance levels at $93.72 and $95.92 provide upside targets
• Support levels at $86.62 and $84.42 offer downside protection
• RSI at 59.40 indicates room for further upside before becoming overbought

Buy Recommendation Based on the strong earnings momentum, expanding margins, and positive technical setup, GEHC appears attractive for purchase at current levels. The stock has support from both fundamental improvements and technical strength, suggesting continued upside potential.

Based on the recent earnings report and market data, here's a comprehensive analysis for GEHC's price prediction in 2025:

Recent Performance and Key Drivers:

Fundamental Catalysts:

• Strong Q4 2024 Performance:
  • EPS of $1.45 vs consensus $1.26
  • Revenue of $5.32B, up 2% YoY
  • Net income of $720M vs $403M YoY
  • Book-to-bill ratio of 1.09x

2025 Guidance Analysis:

• Revenue Growth: 2-3% organic growth
• Adjusted EBIT margin: 16.7-16.8%
• Adjusted EPS: $4.61-$4.75
• Free Cash Flow: Minimum $1.75B

Price Target Analysis:

• Current Analyst Consensus:
  • Rating: Strong Buy
  • Price Target: $100.00
  • Piper Sandler Target: $97.00

Technical Analysis:

• Current Support Levels:
  • S1: $86.62
  • S2: $84.42
  • S3: $80.87
• Resistance Levels:
  • R1: $93.72
  • R2: $95.92
  • R3: $99.47

2025 Price Prediction: Based on the comprehensive analysis, GEHC stock is expected to reach $95-98 by end of 2025, supported by:

1. Strong earnings momentum and margin expansion
2. Strategic partnerships in AI and digital health
3. Positive analyst sentiment and institutional backing

Risk Factors:

• China market softness
• Impact of US tariffs on Chinese products
• Healthcare budget constraints

The S1 support level for GEHC Stock is $86.83 ,The R1 resistant level for GEHC Stock is $93.93.

As of the end of day on 2025-02-26, the price of GEHC Stock was $90.5.

The target price for GEHC Stock according to analyst rating is 102.40, with the highest price target at 110.00 and the lowest at 86.00. Analysts have a Strong Buy rating on GEHC Stock overall.

The market cap of GEHC is $41.5B.

Based on the recent financial data and market performance, GEHC appears to be reasonably valued with some growth potential. The company's Q4 2024 performance showed strong earnings with EPS of $1.45, beating consensus estimates of $1.26. The current P/E ratio of 25.4x represents a premium to its 2022 levels but is justified by improving operational metrics and margin expansion. The company's gross margin improved to 40.52% in 2023, while maintaining a healthy ROE of 16.85%.

Technical indicators suggest a neutral to slightly bullish stance, with RSI at 59.40 showing balanced momentum and the stock trading above all major moving averages. The stock is currently trading at $91.46 in pre-market, within its Fibonacci levels between support at $86.62 and resistance at $93.72.

Recent analyst coverage remains positive, with Piper Sandler maintaining a Buy rating and a $97 price target. The company's 2025 guidance projects organic revenue growth of 2-3% with adjusted EPS of $4.61-$4.75, indicating steady but modest growth expectations.

The stock's current valuation appears justified given its market position, improving margins, and strong order momentum with a book-to-bill ratio of 1.09x.

GE HealthCare Technologies Inc. is a medical technology, pharmaceutical diagnostics, and digital solutions company. It develops, manufactures, and markets a portfolio of products, services, and complementary digital solutions used in the diagnosis, treatment, and monitoring of patients. Its segments include Imaging, Ultrasound, Patient Care Solutions (PCS), and Pharmaceutical Diagnostics (PDx). Its Imaging segment offers a comprehensive portfolio of scanning devices, clinical applications, service capabilities, and digital solutions. Its Ultrasound segment includes ultrasound medical devices and solutions with a portfolio of continuum of care, including screening, diagnosis, treatment, and monitoring of certain diseases. Its PCS segment portfolio is comprised of patient monitoring, anesthesia delivery and respiratory care, diagnostic cardiology, maternal infant care, and consumables and services. Its PDx segment is comprised of two business lines: contrast media and molecular imaging.

Based on the provided data and recent news, here's a comprehensive analysis for GEHC's price prediction in 2030:

Recent Performance and Growth Trajectory

GE Healthcare Technologies (GEHC) has shown strong momentum in recent quarters. The company reported impressive Q4 2024 results with EPS of $1.45, significantly beating consensus estimates of $1.26. Revenue growth was driven by Advanced Visualization Solutions and Pharmaceutical Diagnostics segments, with particular strength in the U.S. market.

Key Growth Drivers Through 2030

1. Innovation and AI Integration

• The company has been heavily investing in AI and digital solutions
• Strategic partnerships like DeepHealth for AI-powered breast cancer screening
• Approximately 10,300 engineers and scientists driving technological advancement

2. Market Expansion

• Recent $138 million investment in Ireland manufacturing facility
• Strong focus on expanding service capabilities through advanced diagnostic solutions
• Growing presence in emerging markets

3. Financial Health

• Robust margin expansion with adjusted EBIT margin expected to reach 16.7%-16.8% in 2025
• Strong order book with book-to-bill ratio of 1.09x
• Consistent earnings growth trajectory

Price Prediction 2030

Based on current growth rates, market position, and industry trends, GEHC stock is projected to reach $165-175 by 2030. This projection is supported by:

• Compound annual growth rate (CAGR) of ~8-9% in earnings through 2030
• Expansion in high-growth segments like AI-enabled diagnostics
• Strong market position in medical imaging and diagnostics
• Continued margin improvement and operational efficiency

The stock is currently trading at $88.98, and with the company's strong fundamentals, technological leadership, and expanding global footprint, it has significant upside potential over the next 5-6 years.

Note: This prediction assumes normal market conditions and successful execution of the company's strategic initiatives. Market volatility, regulatory changes, or major economic events could impact this forecast.

GEHC has a total of 51000 employees.